The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033.

The market is driven by factors such as the growing demand for nucleic acid therapeutics applications to treat chronic and genetic diseases, manufacturing advancement for producing nucleic acid by CDMO (a contract development and manufacturing organization), increasing FDA(Food and Drug Administration) approvals of nucleic acid therapeutics, and increasing investment for the expansion of CDMO manufacturing units.

Market Lifecycle Stage

The global nucleic acid therapeutics CDMO market is developing. The global nucleic acid therapeutics CDMO market has witnessed several collaborations among the market players. The collaborations are aimed at combining capabilities, expanding the customer base, and marketing, among others.

The opportunity for growth of the global nucleic acid therapeutics CDMO market lies in continued research and development activities for manufacturing innovative nucleic acid therapeutics. Many pharmaceutical companies are expanding their businesses and becoming more outsourcing-oriented.

Impact of COVID-19

The COVID-19 pandemic had a low impact on the nucleic acid therapeutics contract development and manufacturing organization (CDMO) sector. The demand for nucleic acid-based COVID-19 vaccines and therapies has led to an increased demand for CDMO services. Many CDMOs have experienced an uptick in orders for services such as nucleic acid synthesis, formulation, and manufacturing of viral vectors.

The future Impact of COVID-19 on the demand and supply across the global nucleic acid therapeutics CDMO market depends on the abilities of stakeholders to withstand unforeseeable scenarios in the future. The intensity of impact due to COVID-19 in the future will depend on the current efforts being made by companies to equip their supply chains with the necessary components and processes to remain responsive.

Market Segmentation:

Segmentation 1: by Product Type

• Standard Nucleic Acid
• Micro-Scale Nucleic Acid
• Large-Scale Nucleic Acid
• Custom Nucleic Acid
• Modified Nucleic Acid
• Primers
• Probes
• Other Nucleic Acid
• Other Services

Segmentation 2: by Technology

• Column-Based Method
• Microarray-Based Method

The global nucleic acid therapeutics CDMO market (by technology) is expected to be dominated by the column-based method.

Segmentation 3: By Chemical Synthesis Method

• Solid-Phase Oligonucleotide Synthesis (SPOS)
• Liquid-Phase Oligonucleotide Synthesis (LPOS)

The global nucleic acid therapeutics CDMO market (by chemical synthesis method) is expected to be dominated by solid-phase oligonucleotide synthesis.

Segmentation 4: By End User

• Pharmaceutical Companies
• Academic Research Institute
• Diagnostic Laboratories

The global nucleic acid therapeutics CDMO market (by end user) is expected to be dominated by pharmaceutical companies.

Segmentation 5: by Region

• North America – U.S., Canada
• Europe – Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, and Rest-of-Asia-Pacific
• Rest-of-the-World

The global nucleic acid therapeutics CDMO market (by region) is dominated by the North America region.

Recent Developments in Global Nucleic Acid Therapeutics CDMO Market

• In June 2021, Danaher Corporation acquired Aldeveron for $9.6 billion. Through this acquisition, the company will expand its manufacturing capacity in plasmid DNA and mRNA.

• In January 2023, Agilent Technologies, Inc. invested $725 million to increase its manufacturing capacity for therapeutic nucleic acids.

• In March 2022, IMM, a partner of VGXI, has recently announced that it received a $12 million grant from the National Institutes of Health (NIH) to support the Phase 1 clinical trial of a DNA vaccine aimed at preventing Alzheimer’s disease. The vaccine will be manufactured using VGXI’s expertise in contract manufacturing of DNA plasmids for human clinical trials, produced in accordance with GMP standards.

• In April 2022, BACHEM partnered with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.

• In September 2021, AGC Biologics expanded the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.

• In August 2022, Codexis and Molecular Assemblies announced the execution of a commercial license and enzyme supply agreement for an optimized TdT enzyme for enzymatic DNA synthesis.

• In June 2020, OliX Pharmaceuticals, Inc. partnered with LGC Biosearch Technologies Inc. to scale up the production of OliX’s OLX301D therapeutic candidate.

Demand – Drivers and Limitations

The following are the drivers for the global nucleic acid therapeutics CDMO market:

• Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
• Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
• Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs

The market is expected to face some limitations as well due to the following challenges:

• Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
• Lack of Expertise in Developing Nucleic Acid Therapeutic

How can this report add value to an organization?

Growth/Marketing Strategy: The global nucleic acid therapeutics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.

Competitive Strategy: The global nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players. The expansion is aimed at increasing the manufacturing capacity. To meet the growing demand for their services, CDMOs are expanding their manufacturing units and investing in new technologies. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Companies Profiled

• Agilent Technologies, Inc.
• AGC Biologics
• Asymchem Inc.
• BACHEM
• BioCina
• CMIC HOLDINGS Co., Ltd.
• Codexis, Inc.
• Danaher Corporation
• Eurofins Scientific
• GeneOne Life Science
• Kaneka Corporation
• LGC Science Group Holdings Limited
• Maravai LifeSciences Holdings, Inc.
• Merck KGaA
• Nippon Shkubai Co., Ltd
• ST Pharm
• Thermo Fisher Scientific Inc.

Table of Contents

1 Market
1.1 Global Market Outlook
1.1.1 Market Overview
1.1.2 Product Definition
1.1.3 Inclusion and Exclusion Criteria
1.1.4 Key Findings
1.2 Industry Outlook
1.2.1 Key Trends
1.2.1.1 Significant Number of Collaborations among Market Players
1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
1.2.2 Opportunity Assessment
1.2.3 Patent Analysis
1.2.3.1 Awaited Technological Developments
1.2.3.2 Patent Filing Trend (by Country)
1.2.3.3 Patent Filing Trend (by Year)
1.2.4 Production Capability
1.2.5 Regulatory Framework
1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
1.3.1 Pre-COVID-19 Phase
1.3.2 During COVID-19
1.3.3 Post-COVID-19 Phase
1.3.3.1 Impact on Demand and Supply
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti‐Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
1.6.3 MicroRNAs (miRNAs)
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Business Dynamics
1.7.1 Impact Analysis
1.7.2 Business Drivers
1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
1.7.3 Business Restraints
1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
1.7.4 Business Opportunities
1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented
2 Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
2.1 Opportunity Assessment
2.2 Growth-Share Matrix
2.3 Solid-Phase Oligonucleotide Synthesis (SPOS)
2.4 Liquid-Phase Oligonucleotide Synthesis (LPOS)
3 Global Nucleic Acid Therapeutics CDMO Market (by Product)
3.1 Opportunity Assessment
3.2 Growth-Share Matrix
3.2.1 Standard Nucleic Acid
3.2.2 Micro-Scale Nucleic Acid
3.2.3 Large-Scale Nucleic Acid
3.2.4 Custom Nucleic Acid
3.2.5 Modified Nucleic Acid
3.2.6 Primers
3.2.7 Probes
3.2.8 Other Nucleic Acid
3.2.9 Other Services
4 Global Nucleic Acid Therapeutics CDMO Market (by Technology)
4.1 Opportunity Assessment
4.2 Growth-Share Matrix
4.3 Column-Based Method
4.4 Microarray-Based Method
5 Global Nucleic Acid Therapeutics CDMO Market (by End Users)
5.1 Opportunity Assessment
5.2 Growth-Share Matrix
5.3 Pharmaceutical Companies
5.4 Academic Institutions
5.5 Diagnostic Laboratories
6 Global Nucleic Acid Therapeutics CDMO Market (by Region)
6.1 North America Nucleic Acid Therapeutics CDMO Market
6.1.1 Key Findings
6.1.2 Market Dynamics
6.1.2.1 Impact Analysis
6.1.3 Market Sizing and Forecast
6.1.3.1 North America Nucleic Acid Therapeutics CDMO Market (by Country)
6.1.3.1.1 U.S.
6.1.3.1.2 Canada
6.2 Europe Nucleic Acid Therapeutics CDMO Market
6.2.1 Key Findings
6.2.2 Market Dynamics
6.2.2.1 Impact Analysis
6.2.3 Market Sizing and Forecast
6.2.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
6.2.3.1.1 Germany
6.2.3.1.2 U.K.
6.2.3.1.3 France
6.2.3.1.4 Spain
6.2.3.1.5 Italy
6.2.3.1.6 Rest-of-Europe
6.3 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
6.3.1 Key Findings
6.3.2 Market Dynamics
6.3.2.1 Impact Analysis
6.3.3 Market Sizing and Forecast
6.3.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
6.3.3.1.1 Japan
6.3.3.1.2 China
6.3.3.1.3 India
6.3.3.1.4 Australia
6.3.3.1.5 Rest-of-Asia-Pacific
6.4 Rest-of-the-World Nucleic Acid Therapeutics CDMO Market
6.4.1 Key Findings
6.4.2 Market Dynamics
6.4.2.1 Impact Analysis
6.4.3 Market Sizing and Forecast
7 Markets – Competitive Benchmarking & Company Profiles
7.1 Competitive Benchmarking
7.1.1 Key Strategies and Developments
7.1.1.1 Funding Activities
7.1.1.2 New Offerings
7.1.1.3 Mergers and Acquisitions
7.1.1.4 Partnerships and Collaborations
7.1.1.5 Business Expansions
7.1.1.6 Regulatory and Legal Activities
7.1.2 Market Share Analysis
7.1.3 Visual Graphics of Key Companies
7.2 Company Profile
7.2.1 Agilent Technologies, Inc.
7.2.1.1 Company Overview
7.2.1.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.1.3 Financials
7.2.1.4 Recent Developments
7.2.1.5 Analyst Perspective
7.2.2 AGC Biologics
7.2.2.1 Company Overview
7.2.2.2 Role of AGC Biologics in the Global Nucleic Acid Therapeutics CDMO Market
7.2.2.3 Financials
7.2.2.4 Recent Developments
7.2.2.5 Analyst Perspective
7.2.3 Asymchem Inc.
7.2.3.1 Company Overview
7.2.3.2 Role of Asymchem Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.3.3 Financials
7.2.3.4 Recent Developments
7.2.3.5 Analyst Perspective
7.2.4 BACHEM
7.2.4.1 Company Overview
7.2.4.2 Role of BACHEM in the Global Nucleic Acid Therapeutics CDMO Market
7.2.4.3 Financials
7.2.4.4 Recent Developments
7.2.4.5 Analyst Perspective
7.2.5 BioCina
7.2.5.1 Company Overview
7.2.5.2 Role of BioCina in the Global Nucleic Acid Therapeutics CDMO Market
7.2.5.3 Recent Developments
7.2.5.4 Analyst Perspective
7.2.6 CMIC HOLDINGS Co., Ltd.
7.2.6.1 Company Overview
7.2.6.2 Role of CMIC HOLDINGS Co., Ltd. In the Global Nucleic Acid Therapeutics CDMO Market
7.2.6.3 Financials
7.2.6.4 Analyst Perspective
7.2.7 Codexis, Inc.
7.2.7.1 Company Overview
7.2.7.2 Role of Codexis, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.7.3 Financials
7.2.7.4 Recent Developments
7.2.7.5 Analyst Perspective
7.2.8 Danaher Corporation
7.2.8.1 Company Overview
7.2.8.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
7.2.8.3 Financials
7.2.8.4 Recent Developments
7.2.8.5 Analyst Perspective
7.2.9 Eurofins Scientific
7.2.9.1 Company Overview
7.2.9.2 Role of Eurofins Scientific in the Global Nucleic Acid Therapeutics CDMO Market
7.2.9.3 Financials
7.2.9.4 Recent Developments
7.2.9.5 Analyst Perspective
7.2.10 GeneOne Life Science
7.2.10.1 Company Overview
7.2.10.2 Role of GeneOne Life Science in the Global Nucleic Acid Therapeutics CDMO Market
7.2.10.3 Recent Developments
7.2.10.4 Analyst Perspective
7.2.11 Kaneka Corporation
7.2.11.1 Company Overview
7.2.11.2 Role of Kaneka Corporation in the Global Nucleic Acid Therapeutics CDMO Market
7.2.11.3 Financials
7.2.11.4 Recent Developments
7.2.11.5 Analyst Perspective
7.2.12 LGC Science Group Holdings Limited
7.2.12.1 Company Overview
7.2.12.2 Role of LGC Science Group Holdings Limited in the Global Nucleic Acid Therapeutics CDMO Market
7.2.12.3 Recent Developments
7.2.12.4 Analyst Perspective
7.2.13 Maravai LifeSciences Holdings, Inc.
7.2.13.1 Company Overview
7.2.13.2 Role of Maravai LifeSciences Holdings, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.13.3 Financials
7.2.13.4 Recent Developments
7.2.13.5 Analyst Perspective
7.2.14 Merck KGaA
7.2.14.1 Company Overview
7.2.14.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
7.2.14.3 Financials
7.2.14.4 Recent Developments
7.2.14.5 Analyst Perspective
7.2.15 Nippon Shkubai Co., Ltd
7.2.15.1 Company Overview
7.2.15.2 Role of Nippon Shokubai Co., Ltd in the Global Nucleic Acid Therapeutics CDMO Market
7.2.15.3 Financials
7.2.15.4 Analyst Perspective
7.2.16 ST Pharm
7.2.16.1 Company Overview
7.2.16.2 Role of ST Pharm in the Global Nucleic Acid Therapeutics CDMO Market
7.2.16.3 Financials
7.2.16.4 Recent Developments
7.2.16.5 Analyst Perspective
7.2.17 Thermo Fisher Scientific Inc.
7.2.17.1 Company Overview
7.2.17.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.17.3 Financials
7.2.17.4 Analyst Perspective

List of Figures

Figure 1: Services Offered by CDMOs
Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 3: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
Figure 4: Global Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
Figure 5: Global Nucleic Acid Therapeutics CDMO Market Segmentation
Figure 6: Global Nucleic Acid Therapeutics CDMO Market: Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
Figure 9: Top-Down Approach (Segment-Wise Analysis)
Figure 10: Significant Number of Collaborations among Market Players in Global Nucleic Acid Therapeutics CDMO Market, 2019-2023
Figure 11: Core CDMO Services
Figure 12: Global Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
Figure 13: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
Figure 14: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
Figure 15: Synthesis Capabilities of Key Companies
Figure 16: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 17: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
Figure 18: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Global Nucleic Acid Therapeutics CDMO Market, 2018-2020
Figure 19: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
Figure 20: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Chemical Synthesis Method), $Billion, 2023-2033
Figure 21: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Chemical Synthesis Method), 2022-2033
Figure 22: Advantages and Disadvantages of Solid-Phase Oligonucleotide Synthesis
Figure 23: Global Nucleic Acid Therapeutics CDMO Market (Solid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
Figure 24: Advantages and Disadvantages of Liquid-Phase Oligonucleotide Synthesis
Figure 25: Global Nucleic Acid Therapeutics CDMO Market (Liquid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
Figure 26: Global Nucleic Acid Therapeutics CDMO Market (by Product)
Figure 27: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Product), $Billion, 2023-2033
Figure 28: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Product), 2022-2033
Figure 29: Global Nucleic Acid Therapeutics CDMO Market (Standard Nucleic Acid), $Billion, 2022-2033
Figure 30: Global Nucleic Acid Therapeutics CDMO Market (Micro-Scale Nucleic Acid), $Billion, 2022-2033
Figure 31: Global Nucleic Acid Therapeutics CDMO Market (Large-Scale Nucleic Acid), $Billion, 2022-2033
Figure 32: Global Nucleic Acid Therapeutics CDMO Market (Custom Nucleic Acid), $Billion, 2022-2033
Figure 33: Global Nucleic Acid Therapeutics CDMO Market (Modified Nucleic Acid), $Billion, 2022-2033
Figure 34: Global Nucleic Acid Therapeutics CDMO Market (Primers), $Billion, 2022-2033
Figure 35: Global Nucleic Acid Therapeutics CDMO Market (Probes), $Billion, 2022-2033
Figure 36: Global Nucleic Acid Therapeutics CDMO Market (Other Nucleic Acid), $Billion, 2022-2033
Figure 37: Global Nucleic Acid Therapeutics CDMO Market (Other Services), $Billion, 2022-2033
Figure 38: Global Nucleic Acid Therapeutics CDMO Market (by Technology)
Figure 39: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Technology), $Billion, 2023-2033
Figure 40: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Technology), 2022-2033
Figure 41: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), $Billion, 2022-2033
Figure 42: Global Nucleic Acid Therapeutics CDMO Market (Microarray-Based Method), $Billion, 2022-2033
Figure 43: Global Nucleic Acid Therapeutics CDMO Market (by End User)
Figure 44: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by End User), $Billion, 2023-2033
Figure 45: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by End User), 2022-2033
Figure 46: Global Nucleic Acid Therapeutics CDMO Market (Pharmaceutical Companies), $Billion, 2022-2033
Figure 47: Global Nucleic Acid Therapeutics CDMO Market (Academic Institutions), $Billion, 2022-2033
Figure 48: Global Nucleic Acid Therapeutics CDMO Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 49: Global Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
Figure 50: North America Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 51: North America Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
Figure 52: U.S. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 53: Canada Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 54: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 55: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
Figure 56: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 57: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 58: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 59: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 60: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 61: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 62: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
Figure 63: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 64: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
Figure 65: Japan Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 66: China Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 67: India Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 68: Australia Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 69: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 70: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 71: Global Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
Figure 72: Funding Activities, January 2018-February 2023
Figure 73: New Offerings, January 2018-February 2023
Figure 74: Mergers and Acquisitions, January 2018-February 2023
Figure 75: Partnerships and Collaborations, January 2018-February 2023
Figure 76: Business Expansions, January 2018-February 2023
Figure 77: Regulatory and Legal Activities, January 2018-February 2023
Figure 78: Global Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
Figure 79: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
Figure 80: Agilent Technologies, Inc: Product Portfolio
Figure 81: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
Figure 82: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 83: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 84: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 85: AGC Biologics: Product Portfolio
Figure 86: AGC Biologics: Overall Financials, $Million, 2019-2021
Figure 87: AGC Biologics: Segment Revenues, $Million, 2019-2021
Figure 88: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
Figure 89: Asymchem Inc.: Product Portfolio
Figure 90: Asymchem Inc.: Overall Financials, $Million, 2021-2022
Figure 91: Asymchem Inc.: Net Revenue (by Segment), $Million, 2021-2022
Figure 92: Asymchem Inc.: Net Revenue (by Region), $Million, 2021-2022
Figure 93: Asymchem Inc.: R&D Expenditure, $Million, 2021-2022
Figure 94: BACHEM: Product Portfolio
Figure 95: BACHEM: Overall Financials, $Million, 2020-2022
Figure 96: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
Figure 97: BACHEM: Net Revenue (by Region), $Million, 2020-2022
Figure 98: BACHEM: R&D Expenditure, $Million, 2020-2022
Figure 99: BioCina: Product Portfolio
Figure 100: CMIC HOLDINGS Co., Ltd.: Product Portfolio
Figure 101: CMIC HOLDINGS Co., Ltd.: Overall Financials, $Million, 2020-2022
Figure 102: CMIC HOLDINGS Co., Ltd.: Segment Revenues, $Million, 2020-2022
Figure 103: CMIC HOLDINGS Co., Ltd.: Net Revenue (by Region), $Million, 2020-2022
Figure 104: CMIC HOLDINGS Co., Ltd.: R&D Expenditure, $Million, 2020-2022
Figure 105: Codexis, Inc: Product Portfolio
Figure 106: Codexis, Inc: Overall Financials, $Million, 2020-2022
Figure 107: Codexis, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 108: Codexis, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 109: Codexis, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 110: Danaher Corporation: Product Portfolio
Figure 111: Danaher Corporation: Overall Financials, $Million, 2020-2022
Figure 112: Danaher Corporation: Net Revenue (by Segment), $Million, 2020-2022
Figure 113: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
Figure 114: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
Figure 115: Eurofins Scientific: Product Portfolio
Figure 116: Eurofins Scientific: Overall Financials, $Million, 2020-2022
Figure 117: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
Figure 118: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
Figure 119: VGXI, Inc.: Product Portfolio
Figure 120: Kaneka Corporation: Product Portfolio
Figure 121: Kaneka Corporation: Overall Financials, $Million, 2019-2021
Figure 122: Kaneka Corporation: Net Revenue (by Segment), $Million, 2019-2021
Figure 123: Kaneka Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 124: Kaneka Corporation: R&D Expenditure, $Million, 2019-2021
Figure 125: LGC Science Group Holdings Limited: Product Portfolio
Figure 126: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
Figure 127: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
Figure 128: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
Figure 129: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
Figure 130: Maravai LifeSciences Holdings, Inc.: Product Portfolio
Figure 131: Maravai LifeSciences Holdings, Inc.: Overall Financials, $Million, 2020-2022
Figure 132: Maravai LifeSciences Holdings, Inc.: Segment Revenues, $Million, 2020-2022
Figure 133: Maravai LifeSciences Holdings, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 134: Maravai LifeSciences Holdings, Inc: R&D Expenditure, $Million, 2020-2022
Figure 135: Merck KGaA: Product Portfolio
Figure 136: Merck KGaA: Overall Financials, $Million, 2020-2022
Figure 137: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
Figure 138: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
Figure 139: Merck KGaA: R&D Expenditure, $Million, 2020-2022
Figure 140: Nippon Shokubai Co., Ltd: Product Portfolio
Figure 141: Nippon Shokubai Co., Ltd: Overall Financials, $Million, 2019-2021
Figure 142: Nippon Shokubai Co., Ltd: Segment Revenues, $Million, 2019-2021
Figure 143: ST Pharm: Product Portfolio
Figure 144: ST Pharm: Overall Financials, $Million, 2019-2021
Figure 145: ST Pharm: Net Revenue (by Segment), $Million, 2019-2021
Figure 146: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 147: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 148: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 149: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 150: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022

List of Tables

Table 1: Global Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
Table 2: Key Questions Answered in the Report
Table 3: Some of the Partnerships and Collaborations in the Global Nucleic Acid Therapeutics CDMO Market
Table 4: Global Nucleic Acid Therapeutics CDMO Market, Key Investment
Table 5: Global Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
Table 7: Advancements in Manufacturing Units of CDMO
Table 8: Companies Offering Standard Nucleic Acid
Table 9: Companies Offering Micro-Scale Nucleic Acid
Table 10: Companies Offering Large-Scale Nucleic Acid
Table 11: Companies Offering Custom Nucleic Acid
Table 12: Companies Offering Modified Nucleic Acid
Table 13: Companies Offering Primers
Table 14: Some of the Companies Offering Probes
Table 15: Companies Offering Other Nucleic Acid
Table 16: Some of the Companies Offering Other Services
Table 17: North America Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Table 18: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
Table 19: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Table 20: Rest-of-the-World Nucleic Acid Therapeutic CDMO Market, Impact Analysis”

The post Nucleic Acid Therapeutics CDMO Market – A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Technology, End User, and Region – Analysis and Forecast, 2023-2033 first appeared on CRI Report.

This report provides a detailed analysis of the Surgical Drainage Devices Market and evaluates the market in light of its categories. The investigation is supported by factual facts and information that was obtained from dependable sources. The report makes projections about the market’s future expansion.

The Surgical Drainage Devices Market grew from USD 2.6 billion in 2022 to USD 4.3 billion by 2032, exhibiting a CAGR of 4.6% during the forecast period.

The research includes graphs of market attractiveness, numerical and statistical information, and graphical representations to give end customers a clear view. Along with knowledge of the distributors and suppliers in the Surgical Drainage Devices Market business, the study also covers crucial product information.

Insights & Overview

This Surgical Drainage Devices Market report employs a proprietary economic model to generate a distinct and trustworthy estimate on market sizing for this equipment/material vertical analysis. The model integrates historical trends horizontal analysis and longitudinal analysis of covered industries.

The study also looks at market drivers, restrictions, opportunities, and problems in the Surgical Drainage Devices Market. The research tackles both qualitative and quantitative components of these marketplaces.

Additionally, the report provides a detailed analysis of the top players profiled in the Surgical Drainage Devices Market as well as the current state of the market’s competition.

The Key players covered in this report:

• Teleflex Incorporated
• Cardinal Health
• Medtronic
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Cook Medical
• Stryker
• Johnson and Johnson
• REDAX
• Smith & Nephew
• Acelity L.P. Inc
• Integra LifeSciences
• Medela AG
• Medline Industries
• Zimmer Biomet
• Other Prominent Players

Scope and Advantages of the report:

1) Evaluate market share for Surgical Drainage Devices Market prospects; monitor market size; follow competitive pharmaceutical sales; and synthesise findings for commercial development and licencing.

2) Create methods and plans to benefit from opportunities presented by Surgical Drainage Devices Market.

3) Current Market Trends and Occurrences, as well as an examination of significant Surgical Drainage Devices Market events.

4) To maintain the accuracy of your brand planning trackers, have a deep awareness of the competition and assess sales statistics.

5) Provides answers to important business queries; supports decision-making in R&D and long-term marketing plans

6) Develop frameworks, forecasting models, and economic models for the sector.

COVID 19 Impacts Analysis

The effects of the COVID-19 pandemic on different industries and verticals are routinely observed in all the domains. The same is covered in research papers that will help you understand the ups and downs in the industries brought on by the COVID-19’s influence. Businesses, strategy strategists, and owners increased their activities and events for their organisations throughout the COVID-19 pandemic to make the post-pandemic environment seem more normal than anticipated.

The analysis covers the factors that are and will continue to fuel the expansion of the industry, as well as evaluating the market’s major potential. Additionally, the total Surgical Drainage Devices Market growth has been predicted for the years 2022–2032 based on historical growth trends, growth drivers, and present and projected trends.

In-depth analyses of market demands, market size, revenue estimates, and projections through 2032 are included in the research. The research divides the information and analyses into groups such as industry, application, location, firm, and competitive landscape. An extensive investigation has been done into Surgical Drainage Devices Market’s market share. The study also includes an analysis of recent changes in the Surgical Drainage Devices Market market.

Region-specific summaries cover areas like North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Each region’s percentage share of the global market is shown.

Surgical Drainage Devices Market is further segmented by region into:
• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – the United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Surgical Drainage Devices Market Segments

• By Product Type
o Active Drainage
o Passive Drainage

• By Application
o General Surgery
o Neurosurgery
o obstetrics/Gynecology
o Orthopedics
o Plastic/Reconstructive Surgery
o Thoracic and Cardiovascular

• By End User
o Hospitals
o Independent Clinics
o Others

Frequently Asked Questions

• What are the prospects for Surgical Drainage Devices Market?
• How will the COVID-19 affect Surgical Drainage Devices Market globally?
• In the Surgical Drainage Devices Market, what are the most typical business strategies?
• What issues do SMEs and big vendors have with Surgical Drainage Devices Market?
• Which geographic area has made the biggest investment in Surgical Drainage Devices Market?
• How recently has Surgical Drainage Devices Market been the subject of research and activity?
• Who are Surgical Drainage Devices Market’s main participants in the field?
• What potential does Surgical Drainage Devices Market have?”

The post Surgical Drainage Devices Market: Segmented: By Product Type (Active Drainage, Passive Drainage), By Application (General Surgery, Neurosurgery, Obstetrics/Gynecology, Orthopedics, Plastic/Reconstructive Surgery, Thoracic and Cardiovascular), By End User (Hospitals, Independent Clinics, Others), And Region – Global Analysis of Market Size, Share & Trends For 2021–2022 And Forecasts To 2032 first appeared on CRI Report.

The Internet banking Comprehensive market report also contains analysis on:

Internet banking Comprehensive market segments: –
By Banking Type:
• Retail Banking
• Corporate Banking
• Investment Banking
By Deployment mode:
• On cloud
• On premises
By Geography
• North America
• Europe
• Asia Pacific
• Rest of the World
• Internet banking Comprehensive market Dynamics
• Internet banking Comprehensive market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved in the Market
• Value Chain of the Market
• Market Drivers and Restraints

The post The Internet banking comprehensive market by banking Type (Retail Banking, Corporate Banking, Investment Banking); by deployment (On Cloud and on premises); and Region –Analysis of Market Size, Share & Trends for 2016 – 2019 and Forecasts to 2029 first appeared on CRI Report.